ProPharma Group, the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, has appointed Dr. Ronald (Ron) Freeze, Ph.D., as the Global Head of Medical Technology (MedTech).
“I am truly honored to have been given the opportunity to lead ProPharma’s MedTech team. I am excited to drive innovative solutions for our clients and leverage my experience to further solidify ProPharma’s position as the world’s largest RCO.” said Dr. Ronald Freeze, Ph.D.
Drawing upon extensive expertise in research and development, regulatory affairs, and comprehensive experience within ProPharma‘s various service lines, Dr. Freeze brings over 25 years of diverse senior leadership experience to his new role. He is known for his ability to deliver successful outcomes, fuel business development and growth, and is uniquely qualified to lead ProPharma’s MedTech team.
In his new role, Dr. Freeze will be accountable for delivering a targeted strategy to assist clients in harmonizing MedTech capabilities across service lines, thereby delivering superior results and industry-leading support to ProPharma’s clients and sponsors. Dr. Freeze’s dedicated efforts will be directed towards advancing ProPharma’s commitment to enhancing and optimizing its global medical device and diagnostics capabilities.
Michael Stomberg, ProPharma’s Chief Executive Officer, said: “I am excited to announce Ron’s appointment as Global Head of MedTech. His impressive experience and proven track record are considerable strengths that will undoubtedly enhance our medical device and diagnostics capabilities. Ron’s appointment reflects our commitment to continuously evolve and meet the growing needs of our clients, ultimately improving the health and safety of patients worldwide.”
“I am truly honored to have been given the opportunity to lead ProPharma’s MedTech team. I am excited to drive innovative solutions for our clients and leverage my experience to further solidify ProPharma’s position as the world’s largest RCO.” said Dr. Ronald Freeze, Ph.D.
ProPharma’s team is committed to continuously advancing and maintaining a leading-edge position in innovation to enhance and optimize its revolutionary Research Consulting Organization (RCO) model. The creation of a dedicated MedTech team emphasizes ProPharma’s research and consulting leadership, and unwavering commitment to delivering inventive solutions and unparalleled support to its valued client partners.
SOURCE: PRweb